Form 4: Achieve Life Sciences CEO Receives Large Equity Grant

CEO Andrew D. Goldberg was granted over 17 million shares in restricted stock units, stock options, and performance-based awards.

Summary

• CEO and President Andrew D. Goldberg received a significant equity compensation package on April 18, 2026.
• The grant includes 1,800,965 Restricted Stock Units (RSUs).
• The grant includes 3,601,929 stock options with an exercise price of $4.25.
• The grant includes 11,706,270 Performance Restricted Stock Units (PRSUs) tied to share price and financial milestones.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is standard practice for public companies.

Positives

• Aligns executive compensation with long-term shareholder value through performance-based vesting.
• Performance-based units require achieving share price milestones ranging from 2x to 9x of a reference price.

Negatives

• Significant potential dilution for existing shareholders due to the issuance of over 17 million new equity instruments.

Risks

• Potential for accelerated vesting under the CEO's employment agreement, which could impact share count volatility.
• Performance milestones for PRSUs are ambitious, requiring significant share price appreciation.

Future Outlook

The equity grants are structured to incentivize long-term performance over the next decade, with vesting schedules extending through 2026 and beyond, contingent on continued service and specific performance hurdles.

Management Comments

• The awards are subject to the terms of the employment agreement, including provisions for accelerated vesting.

Industry Context

StockSavvy.ai notes that large equity grants for biotech CEOs are common, particularly when tied to performance milestones, as they signal management's commitment to long-term clinical and commercial success.

Comparison to Industry Standards

• The use of performance-based restricted stock units (PRSUs) is consistent with industry standards for aligning executive incentives with shareholder interests in the biotechnology sector.
• The 10-year term for options and RSUs is standard for long-term executive retention plans.

Stakeholder Impact

• Shareholders may experience dilution upon the vesting and exercise of these equity instruments.

Next Steps

• Vesting of 1/4 of the RSU award on April 18, 2027.
• Vesting of 1/4 of the stock option award on April 18, 2027.
• Monitoring of share price milestones for PRSU vesting.

Key Dates

Keywords

Achieve Life Sciences, ACHV, Executive Compensation, Form 4, Equity Grant, CEO, Stock Options